SILVER

Small-molecule Inhibitor Leads Versus emerging and neglected RNA viruses

 Coordinatore UNIVERSITE D'AIX MARSEILLE 

 Organization address address: Boulevard Charles Livon 58
city: Marseille
postcode: 13284

contact info
Titolo: Ms.
Nome: Céline
Cognome: Damon
Email: send email
Telefono: 33491998595

 Nazionalità Coordinatore France [FR]
 Totale costo 21˙899˙739 €
 EC contributo 12˙000˙000 €
 Programma FP7-HEALTH
Specific Programme "Cooperation": Health
 Code Call FP7-HEALTH-2010-single-stage
 Funding Scheme CP-IP
 Anno di inizio 2010
 Periodo (anno-mese-giorno) 2010-10-01   -   2015-03-31

 Partecipanti

# participant  country  role  EC contrib. [€] 
1    UNIVERSITE D'AIX MARSEILLE

 Organization address address: Boulevard Charles Livon 58
city: Marseille
postcode: 13284

contact info
Titolo: Ms.
Nome: Céline
Cognome: Damon
Email: send email
Telefono: 33491998595

FR (Marseille) coordinator 2˙855˙357.20
2    KATHOLIEKE UNIVERSITEIT LEUVEN

 Organization address address: Oude Markt 13
city: LEUVEN
postcode: 3000

contact info
Titolo: Dr.
Nome: Elke
Cognome: Lammertyn
Email: send email
Telefono: +32 16 32 06 21
Fax: +32 16 326515

BE (LEUVEN) participant 993˙880.00
3    UNIVERSITAET ZU LUEBECK

 Organization address address: RATZEBURGER ALLEE 160
city: LUEBECK
postcode: 23538

contact info
Titolo: Dr.
Nome: Margret
Cognome: Schwab
Email: send email
Telefono: +49 451 5004062
Fax: +49 451 5004068

DE (LUEBECK) participant 945˙400.00
4    ACADEMISCH ZIEKENHUIS LEIDEN

 Organization address address: Albinusdreef 2
city: LEIDEN
postcode: 2333 ZA

contact info
Titolo: Ms.
Nome: Marlien
Cognome: Vos
Email: send email
Telefono: +31 71 526 1302
Fax: +31 71 526 6761

NL (LEIDEN) participant 744˙609.60
5    AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS

 Organization address address: CALLE SERRANO 117
city: MADRID
postcode: 28006

contact info
Titolo: Mr.
Nome: Eusebio
Cognome: Jiménez Arroyo
Email: send email
Telefono: +34 91 566 8852
Fax: +34 91 566 89 13

ES (MADRID) participant 624˙999.56
6    ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM

 Organization address address: 's Gravendijkwal 230
city: ROTTERDAM
postcode: 3015CE

contact info
Titolo: Mr.
Nome: Wim
Cognome: Leep
Email: send email
Telefono: +31 10 704 3451
Fax: +31 10 704 4760

NL (ROTTERDAM) participant 589˙400.00
7    UNIVERSITA DEGLI STUDI DI MILANO

 Organization address address: Via Festa Del Perdono 7
city: MILANO
postcode: 20122

contact info
Titolo: Dr.
Nome: Stefania
Cognome: Varotto
Email: send email
Telefono: +39 2 50315037
Fax: +39 2 50315040

IT (MILANO) participant 543˙000.00
8    THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD

 Organization address address: University Offices, Wellington Square
city: OXFORD
postcode: OX1 2JD

contact info
Titolo: Ms.
Nome: Linda
Cognome: Polik
Email: send email
Telefono: +44 1865 289800
Fax: +44 1865 289801

UK (OXFORD) participant 500˙000.00
9    INSTITUT PASTEUR

 Organization address address: RUE DU DOCTEUR ROUX 25-28
city: PARIS CEDEX 15
postcode: 75724

contact info
Titolo: Dr.
Nome: Nadia
Cognome: Khelef
Email: send email
Telefono: +33 1 40 61 33 78
Fax: +33 1 40 61 39 40

FR (PARIS CEDEX 15) participant 418˙959.60
10    CENTRUM VOOR INNOVATIE EN STIMULATIEVAN MEDICIJNONTWIKKELING LEUVEN VZW

 Organization address address: MINDERBROEDERSTRAAT 12
city: LEUVEN
postcode: 3000

contact info
Titolo: Dr.
Nome: Patrick
Cognome: Chaltin
Email: send email
Telefono: +32 16 32 65 23
Fax: +32 16 33 29 68

BE (LEUVEN) participant 403˙000.00
11    Global Phasing Limited

 Organization address address: Newton Road 43
city: CAMBRIDGE
postcode: CB2 8AL

contact info
Titolo: Dr.
Nome: Gerard
Cognome: Bricogne
Email: send email
Telefono: +1223 353033
Fax: +1223 366889

UK (CAMBRIDGE) participant 400˙000.00
12    UNIVERSITAETSKLINIKUM HEIDELBERG

 Organization address address: IM NEUENHEIMER FELD 672
city: HEIDELBERG
postcode: 69120

contact info
Titolo: Mr.
Nome: Thorsten
Cognome: Brietz
Email: send email
Telefono: +49 6221 56 7086
Fax: +49 6221 56 5460

DE (HEIDELBERG) participant 400˙000.00
13    UNIVERSITAET HAMBURG

 Organization address address: EDMUND-SIEMERS-ALLEE 1
city: HAMBURG
postcode: 20146

contact info
Titolo: Mr.
Nome: Jens
Cognome: Bricke
Email: send email
Telefono: +49 40 428 38 2880
Fax: +49 40 428 38 2892

DE (HAMBURG) participant 375˙000.00
14    UNIVERSITAET INNSBRUCK

 Organization address address: INNRAIN 52
city: INNSBRUCK
postcode: 6020

contact info
Titolo: Dr.
Nome: Kurt
Cognome: Habitzel
Email: send email
Telefono: +43 512 507 9051
Fax: +43 512 507 2607

AT (INNSBRUCK) participant 375˙000.00
15    RIBOXX GMBH

 Organization address address: MEISSNER STRASSE 191
city: RADEBEUL
postcode: 1445

contact info
Titolo: Dr.
Nome: Jacques
Cognome: Rohayem
Email: send email
Telefono: +49 351 4586200
Fax: +49 351 4586314

DE (RADEBEUL) participant 361˙720.00
16    CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE

 Organization address address: Rue Michel -Ange 3
city: PARIS
postcode: 75794

contact info
Titolo: Mr.
Nome: Jocelyn
Cognome: Mere
Email: send email
Telefono: +33 4 67 61 35 35
Fax: +33 4 67 04 32 36

FR (PARIS) participant 350˙000.00
17    UNIVERSITAET LEIPZIG

 Organization address address: RITTERSTRASSE 26
city: LEIPZIG
postcode: 4109

contact info
Titolo: Mr.
Nome: Gerhard
Cognome: Fuchs
Email: send email
Telefono: +49 341 9735012
Fax: +49 341 9735009

DE (LEIPZIG) participant 282˙674.60
18    UNIVERSITEIT UTRECHT

 Organization address address: Heidelberglaan 8
city: UTRECHT
postcode: 3584 CS

contact info
Titolo: Mrs.
Nome: Louise
Cognome: Van Der Kaaden
Email: send email
Telefono: +31 30 2535388
Fax: +31 30 2532333

NL (UTRECHT) participant 230˙017.28
19    "SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES"

 Organization address address: ZU CHONG ZHI ROAD ZHANG JIANG High-Tech Park 555
city: SHANGHAI
postcode: 201203

contact info
Titolo: Ms.
Nome: Jianmei
Cognome: Shi
Email: send email
Telefono: +86 21 50807042
Fax: +86 21 50807042

CN (SHANGHAI) participant 175˙000.00
20    STICHTING KATHOLIEKE UNIVERSITEIT

 Organization address address: GEERT GROOTEPLEIN NOORD 9
city: NIJMEGEN
postcode: 6525 EZ

contact info
Titolo: Mr.
Nome: Wim
Cognome: Van Oijen
Email: send email
Telefono: +31 243618937
Fax: +31 243540529

NL (NIJMEGEN) participant 144˙982.72
21    PIKE PHARMA GMBH

 Organization address address: TECHNOPARKSTRASSE 1
city: ZUERICH
postcode: CH-8005

contact info
Titolo: Dr.
Nome: Ulrich
Cognome: Kessler
Email: send email
Telefono: +41 44 633 73 53
Fax: +41 44 633 13 67

CH (ZUERICH) participant 144˙673.94
22    FREIE UNIVERSITAET BERLIN

 Organization address address: Kaiserswertherstrasse 16-18
city: BERLIN
postcode: 14195

contact info
Titolo: Mr.
Nome: Carsten
Cognome: Malmwieck
Email: send email
Telefono: +49 30 83852990
Fax: +49 30 83853448

DE (BERLIN) participant 142˙325.42
23    KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY

 Organization address address: JANG DONG YUSUNG GU 100
city: DAEJEON
postcode: 305606

contact info
Titolo: Dr.
Nome: Youngjoo
Cognome: Ko
Email: send email
Telefono: +82 42 860 7760
Fax: +82 42 860 7761

KR (DAEJEON) participant 0.00
24    National Central University

 Organization address address: JHONGDA ROAD 300
city: Jhongli
postcode: 320

contact info
Titolo: Ms.
Nome: Yu-Jin
Cognome: Cheng
Email: send email
Telefono: +886 35 715131
Fax: +886 35 737322

TW (Jhongli) participant 0.00

Mappa


 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

virus    leads    models    compound    human    viruses    vitro    cov    economic    protein    structural    neglected    rna    pipeline    small    molecules    medicinal    proteins    drug    hits    drugs    inhibitor    mers    inhibitors    molecule    group    antiviral    discovery    silver    dengue    proof    promising    optimisation    sars    viral    screening    versus    relatively    enzymes    compounds   

 Obiettivo del progetto (Objective)

'RNA virus infections kill millions of humans annually, largely due to the lack of suitable vaccines and drugs to control them. This problem is addressed in this FP7 call and in response a consortium of Europe’s and Asia’s leading molecular virologists, structural biologists, medicinal chemists and bioinformaticians has been brought together to generate a state-of-the-art drug discovery and design programme. The project aims to identify Small molecule Inhibitor Leads Versus Emerging and neglected RNA viruses (SILVER). It will focus its activities on selected medically important RNA viruses for which the development of drugs is considered essential (Dengue-, entero- and paramyxoviruses), whereas other relatively neglected and/or emerging RNA viruses will be explored to identify the most promising viral protein targets and antiviral compounds. A pipeline strategy has been developed to enable the inclusion in SILVER of viruses at all levels of existing knowledge. Targets for potential drugs include infectious virus, structurally characterised viral enzymes and other proteins. Leads for currently available antiviral drugs have been identified by screening compound libraries in virus-infected cell culture systems and in vitro assays using purified viral enzymes. Selective inhibitors of viral replication have also been (and are being) derived using detailed structural knowledge of viral proteins and structure-based drug design. Hits will be assayed using individual viral protein targets and replicative proteins in complex with viral RNA. The potential protective activity of the most potent inhibitors, that have a favourable (in vitro) ADME-tox profile, will be assessed in relevant infection models in animals. Licenses on promising compounds or compound classes will be presented to the interested pharmaceutical industry. The SILVER consortium will be well placed to play a major role in contributing to the international effort to develop strategies to improve world health.'

Introduzione (Teaser)

EU funding is continuing to work on therapies to tackle emerging and neglected RNA viruses. Diseases include the newly emerging human MERS and severe acute respiratory syndrome (SARS).

Descrizione progetto (Article)

The 'Small-molecule inhibitor leads versus emerging and neglected RNA viruses' (http://www.silver-europe.com/ (SILVER)) project has completed another year of research on the priority group A viruses and relatively neglected and or emerging group B viruses.

The first two years of the SILVER project resulted in many hits and leads against a huge range of RNA viruses. Research response is keeping up with the all-too-rapid evolution and opportunistic behaviour of viruses.

The unexpected emergence of the human MERS-coronavirus (MERS CoV) in Saudi Arabia initiated an immediate response from the SILVER steering committee. Consequently, the project's 'Outbreak Pipeline' was activated to organise investigation into this potentially highly pathogenic virus.

The focus on optimisation of hit-to-lead has intensified delivering several priority lead compounds for a wide range of RNA viruses.

The researchers have identified and tested a very broad-spectrum inhibitor T705. There is also progress on an inhibitor against dengue virus and a patent application is imminent. For MERS CoV, there are several promising hits, all from a library of FDA-approved compounds as a spin-off of previous work on the related SARS CoV.

Importantly, several new mouse models have been developed with a variety of viruses. These will enable a much greater level of study of proof of concept through in vivo studies, as the new inhibitors are moved from hits to promising leads.

For crystallography there have been continuous software updates for high-throughput screening of possible target-ligand complexes used ultimately in inhibitor identification. Use of medicinal chemistry, mechanism of action studies, determination of toxicity profiles, proof-of-concept experiments for the most promising molecules and compounds is intensifying lead optimisation.

SILVER activities could result in the discovery of two or more new antiviral molecules or compounds after rigorous proof of concept trials in relevant animal models. Quality of life and economic growth are intimately linked and are frequently seriously affected by emerging viruses. Discovery of safe and effective viral inhibitors will help to alleviate epidemic outbreaks that have an enormous social and economic cost.

Altri progetti dello stesso programma (FP7-HEALTH)

STRONG (2012)

European Consortium for the Study of a Topical Treatment of Neovascular Glaucoma

Read More  

THE ONE STUDY (2010)

A Unified Approach to Evaluating Cellular Immunotherapy in Solid Organ Transplantation

Read More  

SYSCLAD (2012)

Systems prediction of Chronic Lung Allograft Dysfunction

Read More